262 related articles for article (PubMed ID: 26843444)
1. Oral nucleos(t)ide analogues reduce recurrence and death in chronic hepatitis B-related hepatocellular carcinoma.
Wong GL; Tse YK; Chan HL; Yip TC; Tsoi KK; Wong VW
Aliment Pharmacol Ther; 2016 Apr; 43(7):802-13. PubMed ID: 26843444
[TBL] [Abstract][Full Text] [Related]
2. Nucleos(t)ide analogues associated with a reduced risk of hepatocellular carcinoma in hepatitis B patients: a population-based cohort study.
Wang JP; Kao FY; Wu CY; Hung YP; Chao Y; Chou YJ; Li CP
Cancer; 2015 May; 121(9):1446-55. PubMed ID: 25537961
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: A cohort study of 53,500 subjects.
Wong GL; Tse YK; Wong VW; Yip TC; Tsoi KK; Chan HL
Hepatology; 2015 Sep; 62(3):684-93. PubMed ID: 25973979
[TBL] [Abstract][Full Text] [Related]
4. The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy.
Coffin CS; Rezaeeaval M; Pang JX; Alcantara L; Klein P; Burak KW; Myers RP
Aliment Pharmacol Ther; 2014 Dec; 40(11-12):1262-9. PubMed ID: 25312649
[TBL] [Abstract][Full Text] [Related]
5. Comparison of overall survival between antiviral-induced viral suppression and inactive phase chronic hepatitis B patients.
Cho YY; Lee JH; Chang Y; Nam JY; Cho H; Lee DH; Cho EJ; Lee DH; Yu SJ; Lee JM; Kim YJ; Yoon JH
J Viral Hepat; 2018 Oct; 25(10):1161-1171. PubMed ID: 29741286
[TBL] [Abstract][Full Text] [Related]
6. Long-term use of oral nucleos(t)ide analogues for chronic hepatitis B does not increase cancer risk - a cohort study of 44 494 subjects.
Wong GL; Tse YK; Yip TC; Chan HL; Tsoi KK; Wong VW
Aliment Pharmacol Ther; 2017 May; 45(9):1213-1224. PubMed ID: 28239880
[TBL] [Abstract][Full Text] [Related]
7. Determinants of hepatocellular carcinoma in cirrhotic patients treated with nucleos(t)ide analogues for chronic hepatitis B.
Hsu YC; Wu CY; Lane HY; Chang CY; Tai CM; Tseng CH; Lo GH; Perng DS; Lin JT; Mo LR
J Antimicrob Chemother; 2014 Jul; 69(7):1920-7. PubMed ID: 24576950
[TBL] [Abstract][Full Text] [Related]
8. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues.
Yip TC; Wong GL; Chan HL; Tse YK; Lam KL; Lui GC; Wong VW
J Hepatol; 2019 Mar; 70(3):361-370. PubMed ID: 30367899
[TBL] [Abstract][Full Text] [Related]
9. Randomized clinical trial: Nucleos(t)ide analogues improved survival of CHB-related HCC patients via reducing severity and progression of malignancy.
Wang Y; Xiang X; Chen L; Cao Z; Bao R; Zhou H; Tang W; Lu J; Lin L; Xie Q; Bao S; Wang H
Oncotarget; 2016 Sep; 7(36):58553-58562. PubMed ID: 27329718
[TBL] [Abstract][Full Text] [Related]
10. Long-term prognosis of patients with hepatitis B infection: causes of death and utility of nucleos(t)ide analogue therapy.
Tada T; Kumada T; Toyoda H; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabtake S; Ito T
J Gastroenterol; 2015 Jul; 50(7):795-804. PubMed ID: 25376770
[TBL] [Abstract][Full Text] [Related]
11. HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy.
Hosaka T; Suzuki F; Kobayashi M; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Akuta N; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
Liver Int; 2010 Nov; 30(10):1461-70. PubMed ID: 20840396
[TBL] [Abstract][Full Text] [Related]
12. Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high risk.
Ren P; Cao Z; Mo R; Liu Y; Chen L; Li Z; Zhou T; Lu J; Liu Y; Guo Q; Chen R; Zhou H; Xiang X; Cai W; Wang H; Bao S; Xu Y; Gui H; Xie Q
Expert Opin Biol Ther; 2018 Oct; 18(10):1085-1094. PubMed ID: 30182763
[TBL] [Abstract][Full Text] [Related]
13. Benefits of long-term therapy with nucleos(t)ide analogues in treatment-naïve patients with chronic hepatitis B.
Wei L; Kao JH
Curr Med Res Opin; 2017 Mar; 33(3):495-504. PubMed ID: 27882776
[TBL] [Abstract][Full Text] [Related]
14. Nucleot(s)ide analogues for hepatitis B virus-related hepatocellular carcinoma after curative treatment: a systematic review and meta-analysis.
Sun P; Dong X; Cheng X; Hu Q; Zheng Q
PLoS One; 2014; 9(7):e102761. PubMed ID: 25058587
[TBL] [Abstract][Full Text] [Related]
15. Association between nucleos(t)ide analog and tumor recurrence in hepatitis B virus-related hepatocellular carcinoma after radiofrequency ablation.
Lee TY; Lin JT; Zeng YS; Chen YJ; Wu MS; Wu CY
Hepatology; 2016 May; 63(5):1517-27. PubMed ID: 26426978
[TBL] [Abstract][Full Text] [Related]
16. Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts hepatocellular carcinoma incidence and recurrence in nucleos(t)ide analogue therapy for chronic hepatitis B.
Kawaguchi K; Honda M; Ohta H; Terashima T; Shimakami T; Arai K; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Komura T; Unoura M; Kaneko S
J Gastroenterol; 2018 Jun; 53(6):740-751. PubMed ID: 28849280
[TBL] [Abstract][Full Text] [Related]
17. Real-world study on clinical outcomes of nucleos(t)ide analogues antiviral therapy in patients with chronic hepatitis B.
Sun Y; Zhang Y; Xu Y; Shu M; Bonroy K; Qiu H; Cai W
Epidemiol Infect; 2019 Jan; 147():e193. PubMed ID: 31364558
[TBL] [Abstract][Full Text] [Related]
18. Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: A propensity score landmark analysis.
Hsiang JC; Wong GL; Tse YK; Wong VW; Yip TC; Chan HL
J Hepatol; 2015 Nov; 63(5):1190-7. PubMed ID: 26208777
[TBL] [Abstract][Full Text] [Related]
19. Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog.
Hui VW; Yip TC; Wong VW; Tse YK; Chan HL; Lui GC; Wong GL
Clin Transl Gastroenterol; 2021 Mar; 12(3):e00324. PubMed ID: 33750746
[TBL] [Abstract][Full Text] [Related]
20. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review.
Papatheodoridis GV; Lampertico P; Manolakopoulos S; Lok A
J Hepatol; 2010 Aug; 53(2):348-56. PubMed ID: 20483498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
